Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Large-scale testing (Phase 3)Not Yet RecruitingNCT07754123
What this trial is testing

Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC

Who this might be right for
Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd. 206
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Early research (Phase 1)Study completedNCT03846310
What this trial is testing

Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer MetastaticNon Small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of Lung+1 more
Arcus Biosciences, Inc. 77
Early research (Phase 1)Ended earlyNCT04862780
What this trial is testing

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+21 more
Blueprint Medicines Corporation 177
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Large-scale testing (Phase 3)UnknownNCT04239833
What this trial is testing

SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 240
Early research (Phase 1)Study completedNCT01859026
What this trial is testing

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Who this might be right for
Lung CancerNon-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 43
Large-scale testing (Phase 3)Active Not RecruitingNCT07183189
What this trial is testing

SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 582
Not applicableNot Yet RecruitingNCT06117644
What this trial is testing

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIA+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 30
Large-scale testing (Phase 3)Looking for participantsNCT06417814
What this trial is testing

Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-small Cell Lung Cancer
AstraZeneca 744
Large-scale testing (Phase 3)Active Not RecruitingNCT04923906
What this trial is testing

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 624
Testing effectiveness (Phase 2)Ended earlyNCT04099836
What this trial is testing

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Who this might be right for
Non Small Cell Lung Cancer
Duke University 7
Testing effectiveness (Phase 2)Ended earlyNCT00988169
What this trial is testing

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 6
Early research (Phase 1)Ended earlyNCT04622072
What this trial is testing

XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Sihuan Pharmaceutical Holdings Group Ltd. 21
Large-scale testing (Phase 3)Active Not RecruitingNCT04351555
What this trial is testing

Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 358
Post-approval studies (Phase 4)Not Yet RecruitingNCT07469488
What this trial is testing

A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)VTE (Venous Thromboembolism)Rash Due to Epidermal Growth Factor Receptor Inhibitors+1 more
Shanghai Pulmonary Hospital, Shanghai, China 122
Large-scale testing (Phase 3)Not Yet RecruitingNCT06323148
What this trial is testing

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Who this might be right for
Lung CancerEGFR Gene MutationMinimal Residual Disease
Fudan University 226
Early research (Phase 1)Study completedNCT06525246
What this trial is testing

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Who this might be right for
Stage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung CancerStage IV Non-small Cell Lung Cancer+2 more
Ono Pharmaceutical Co., Ltd. 78
Next Page